|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
|
18182111 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association of DNA mismatch repair deficiencies in the development and/or progression of epithelial ovarian cancers, the relationship between replication errors (RERs) and genetic alterations in three genes (p53, c-erbB2, K-ras) and loss of heterozygosity (LOH) on 6q27 was investigated in 70 patients with epithelial ovarian cancers.
|
11172909 |
2001 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
|
16682283 |
2006 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of HER2 codon 655 polymorphism with ovarian cancer.
|
26666819 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.
|
29535531 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A pilot study on relationships of selected molecular factors [erbB-1, erbB-2, erbB-3, and c-myc oncogene average gene copy numbers (AGCN); steroid receptors and pS2 gene expression; tumor cells' DNA values] to the ex vivo chemosensitivity of ovarian cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed.
|
10961689 |
2000 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also identified two haplotypes in ERBB2 associated with an increased OC risk (P(global)=0.034) and a haplotype in BRAF that had a protective effect (P(global)=0.005).
|
19240718 |
2009 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
|
2470152 |
1989 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Archival tissues from 23 cases of papillary serous ovarian carcinoma (9 cases of stage I and 14 cases of stage III) were analyzed by FISH using a HER-2/neu probe and a chromosome 17 centromere control probe.
|
10409445 |
1999 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
|
11351242 |
2001 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.
|
16607561 |
2006 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that small interfering RNA (siRNA) can silence the expression of Her-2/neu in models of human breast or ovarian cancer through retrovirus-mediated transfer of an siRNA against Her-2/neu.
|
14625284 |
2004 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
CTD_human |
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
|
28811376 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER-2/neu is a proto-oncogene associated with poor prognosis in women with breast and ovarian carcinoma.
|
10202671 |
1999 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplifications and overexpression of various EGFR family members, including EGFR, Her2, and ErbB3, have been reported in epithelial ovarian cancer.
|
21364581 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tests for the HER2 gene copies per tumor cell either before or after correction of chromosome-17 can be applied as a potentially valuable tool to analyze the HER2 status in mucinous EOC.
|
24656091 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
No genomic rearrangements by Southern blotting were seen in the brcAI candidate gene estradiol 17 beta dehydrogenase 2 (17hsd2), or in erbB2, prohibition (phb) and nmeI (previously nm23-HI).
|
8098014 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
|
7906608 |
1994 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases.
|
30822630 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CTLs were capable of lysing low doses of peptides pulsed into target cells or OC Her-2/neu(+) tumors.
|
19115932 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aptamer-radionuclide conjugate was evaluated for cellular HER2-specific binding, saturation affinity, and cellular internalization in SKOV-3 and MCF-7 cells, and its biodistribution properties were assessed in normal and SKOV-3 tumor-bearing mice.
|
23953624 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that both chromosome-17 corrected and uncorrected HER2 gene copies correlated significantly with HER2 IHC result categories; and tests for the HER2 gene copies per tumor cell either before or after correction for chromosome-17 can be applied as a potentially valuable tool in analyzing the HER2 status in EOC.
|
21046136 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Forty-five patients with stage III or IV HER-2/neu overexpressing breast or ovarian cancer were evaluated for HER-2/neu specific T cell and antibody immunity.
|
11072789 |
2000 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that Gigantoxin-4-4D5 scFv exerted a highly cytotoxic effect on the HER2/neu-positive ovarian carcinoma SK-OV-3 cell line.
|
27063011 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, HER2 gene status was evaluated in a large, multicentric series of 320 patients with advanced ovarian cancer, including 243 patients enrolled in a multicenter prospective clinical trial of paclitaxel/carboplatin-based chemotherapy.
|
17987122 |
2007 |